A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Summary

The purpose of the study is to evaluate 1. The microbiological response and clinical efficacy of SPR720 compared with placebo in participants with nontuberculous mycobacteria pulmonary disease (NTM-PD). 2. The safety and tolerability of SPR720 in participants with NTM- PD 3. The pharmacokinetic (PK) of SPR719, active moiety, following orally (po) administered prodrug SPR720 in participants with NTM-PD.

Timeline

Start

2022-12-14

Primary completion

2024-10-08

Completion

2024-12-02

Publications

• Ussery XT, Bhatt N, Critchley IA, Wong SL, Pottage JC Jr, Melnick D, Hamed KA. Randomized study of the efficacy, safety, and pharmacokinetics of SPR720 for the treatment of Mycobacterium avium complex pulmonary disease. Sci Rep. 2026 Feb 20;16(1):10063. doi: 10.1038/s41598-026-40505-7.

Drugs

Indications